Pulmonary artery hypertension (PAH) is a life threatening disease but it shows less response to traditional therapeutic regimens. Mesenchymal stem cells can be a promising resource for the treatment of refractory diseases such as PAH. However, prophylactic use of human umbilical cord blood derived mesenchymal stem cells (hUCB-MSCs) in PAH models are still controversial. Therefore, we investigated the differential effects such as hemodynamics, pathologic finding and gene expressions of hUCB-MSCs according to transfusion timing.Design and method:
6-week Sprague Dawley rats were used in this research. The experimental groups were divided into the control group, the monocrotaline (M) group (60 mg/kg) and the treatment groups which were subdivided into two groups, the UA group (hUCB-MSCs were administered 1 day after MCT injection); the UB group (hUCB-MSCs are administered 1 week after MCT injection). Hemodynamics, pathological changes and protein expressions were investigated.Results:
Mean right ventricular pressure (RVP) was significantly reduced in all U groups compared with the M group at weeks 2 and 4. RV/RV + S ratio was significantly decreased in the UA and UB groups compared with the M group at week 1. RV/RV + S ratio was decreased in the UB group compared UA group at week 4. In aspect of pathological changes, medial wall thickness and the number of intra-acinar arteries were significantly improved in two treatment groups at week 4. The protein expressions of endothelin-1, B cell leukemia lymphoma-2 and vascular endothelial growth factor in the lung tissues were significantly decreased in the UA and UB group at week 4. Collagen I and III protein expressions in the heart tissues were significantly decreased in the UB group compared with UA group.Conclusions:
A prophylactic injection of hUCB-MSCs was not as effective as a treatment injection after the occurrence of PAH in MCT rats.